Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering Corporation (Nasdaq: IMRX) announces its participation in the 21st Annual Needham Virtual Healthcare Conference, scheduled for April 11-14, 2022. Management, including CEO Ben Zeskind and CFO Biren Amin, will present insights on the company's oncology pipeline and business strategy. The presentation will occur on April 12 from 3:45-4:25 PM ET. Immuneering's lead candidate, IMM-1-104, is a dual-MEK inhibitor targeting RAS mutations in advanced tumors, aimed at sparing healthy cells. The company uses a proprietary bioinformatics platform to advance its pipeline.
Immuneering Corporation (Nasdaq: IMRX) reported financial results for Q4 and full year 2021, highlighting significant advancements in their lead product candidate, IMM-1-104. This candidate shows broad activity against various tumor models with activating mutations. The company holds $150.2 million in cash, ensuring funding through Q3 2024. Notably, they expect to file an IND for IMM-1-104 in Q3 2022. Research and development expenses increased to $26.5 million for 2021, primarily due to preclinical initiatives. The net loss for the year was $33.5 million, or $2.46 per share.
Immuneering Corporation (Nasdaq: IMRX) showcases its oncology pipeline that spares healthy cells by modulating signaling dynamics. The company will participate in two investor conferences in March 2022 to discuss its product candidates and business strategy, including a panel at the Cowen 42nd Annual Health Care Conference and a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. The lead product candidate, IMM-1-104, targets RAS mutations in advanced tumors, supported by a unique translational bioinformatics approach.
Immuneering Corporation (Nasdaq: IMRX) recently announced participation in two investor conferences to discuss its innovative oncology pipeline. The first presentation will be at the B. Riley Securities Virtual Oncology Investor Conference on January 28, 2022, at 12:00 pm ET, followed by a Guggenheim Virtual Oncology Conference on February 9, 2022, at 10:00 am ET. The company's proprietary pipeline focuses on oncology and neuroscience drug candidates designed to target tumor cells while sparing healthy cells. These insights stem from a robust translational bioinformatics platform.
Immuneering Corporation (Nasdaq: IMRX) announced the appointment of Diana F. Hausman, M.D. to its Board of Directors, enhancing its leadership with her >20 years of clinical drug development experience. Dr. Hausman, previously Chief Medical Officer at Lengo Therapeutics, will contribute significantly to advancing Immuneering's pipeline, notably the lead candidate IMM-1-104, a dual-MEK inhibitor for RAS mutant tumors. Her extensive background in oncology showcases the company’s commitment to improving therapeutic options for cancer patients.
Immuneering Corporation (Nasdaq: IMRX) has revealed promising preclinical data for its lead product candidate, IMM-1-104, indicating its potential to inhibit tumor growth in NRAS mutant melanoma models. This data, which compares IMM-1-104 to binimetinib, suggests superior efficacy, achieving tumor growth inhibition rates between 74.9% and 99.9%. The company plans to submit an Investigational New Drug application to the FDA in Q3 2022 and aims to commence human clinical trials by Q4 2022. The findings underscore IMM-1-104’s potential as a therapeutic alternative in treating RAS mutant tumors.
Immuneering Corporation (Nasdaq: IMRX) has appointed Rimma Steinhertz, Ph.D., PMP, as Vice President of Project and Alliance Management, effective immediately. Dr. Steinhertz brings extensive experience in oncology and neurology, previously holding leadership roles at Glenmark Pharmaceuticals and Merck. In her new role, she will work with the leadership team to advance the clinical trials of IMM-1-104, a selective dual-MEK inhibitor targeting RAS mutant tumors. The company's strategy includes collaborations to enhance treatment approaches.
Immuneering Corporation (Nasdaq: IMRX) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. This addition, less than five months post-initial public offering, aims to enhance visibility within the investment community. CEO Ben Zeskind highlighted the promising performance of the company’s lead candidate, IMM-1-104, demonstrating tumor growth inhibition across multiple animal models. The firm focuses on developing treatments for solid tumors driven by oncogenic mutations, supported by a pipeline encompassing six other oncology and two neuroscience programs.
Immuneering Corporation (Nasdaq: IMRX) announced its participation in several December investor conferences to discuss its oncology pipeline and business strategy. Key events include the Piper Sandler Global Healthcare Conference and Evercore ISI HealthCONx Conference, where executives will engage in investor meetings and fireside chats. The company focuses on developing therapies that target oncogenic signaling pathways, notably with its lead product candidate IMM-1-104, aimed at advanced solid tumors. Immuneering emphasizes its proprietary platform driven by translational bioinformatics.
Immuneering Corporation (Nasdaq: IMRX) announced its participation in the upcoming Jefferies 2021 London Healthcare Conference, scheduled for November 16-19, 2021. Company executives, including CEO Ben Zeskind, will present virtually on November 18 at 08:00 GMT (03:00 AM ET). The presentation will highlight their innovative pipeline of oncology drug candidates, particularly focusing on their lead product, IMM-1-104, a selective dual-MEK inhibitor for advanced solid tumors. A live webcast will be available from November 18 at 3:00 AM ET, with on-demand access until November 19 at 12:00 PM ET.